Trial Details
COMPLETEDBasic Information
| Clinical ID | c2252 |
|---|---|
| Identifier | NCT03782376 |
| Trial Title | A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Crohn Disease |
| Interventions | DRUG: Ustekinumab approximately 6 mg/kg (IV)|DRUG: Placebo (SC)|DRUG: Placebo (IV)|DRUG: Ustekinumab 90 mg (SC) Group 1|DRUG: Ustekinumab 90 mg (SC) Group 2 |
Participant Information
| Sponsor | Janssen-Cilag Ltd. |
|---|---|
| City | La Jolla |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2018-12-20 |
|---|---|
| Primary Completion Date | 2022-08-19 |
| Completion Date | 2023-01-10 |